


PHARMACEUTICAL 2022



EAGLE PHARMACEUTICALS INC. Rank 68 of 475





PHARMACEUTICAL 2022





EAGLE PHARMACEUTICALS INC. Rank 68 of 475

The relative strengths and weaknesses of EAGLE PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of EAGLE PHARMACEUTICALS INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 398% points. The greatest weakness of EAGLE PHARMACEUTICALS INC. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 53% points.

The company's Economic Capital Ratio, given in the ranking table, is 96%, being 372% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	172,606
Cost of Goods Sold	31,528
Intangible Assets	50,414
Liabilities, Current	74,376
Liabilities, Non-Current	2,903
Other Assets	29,076
Other Compr. Net Income	-94
Other Expenses	14,731
Other Liabilities	0
Other Net Income	-7,317
Property and Equipment	1,636
Research and Development	51,275
Revenues	171,546
Selling, General and Administrative Expense	75,322

Output Variable	Value in 1000 USD
Assets	253,732
Liabilities	77,279
Expenses	172,856
Stockholders Equity	176,453
Net Income	-8,627
Comprehensive Net Income	-8,674
Economic Capital Ratio	96%